Guggenheim raised the firm’s price target on Elevance Health (ELV) to $398 from $360 and keeps a Buy rating on the shares. Ahead of Q3 earnings, the firm frames a “reasonable” $20-$21 2025 EPS “floor” to consider and provides “high-level thoughts deriving $27-$28 as a starting point” for 2026 EPS, the analyst tells investors in a preview. The firm believes the debate on 2026 EPS is likely to intensify, particularly considering Elevance’s recent run-up amid significant end-market disruption, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target raised to $412 from $330 at Wells Fargo
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Trade: White House announces drug pricing deal with Pfizer
- Health Insurance subsidies central to government shutdown negotiation, WSJ says
- Trump says working on reducing cost of health insurance